Zacks Research upgraded shares of Satellos Bioscience (NASDAQ:MSLE – Free Report) from a strong sell rating to a hold rating in a research note published on Thursday morning,Zacks reports.
A number of other analysts have also recently commented on the stock. Craig Hallum initiated coverage on shares of Satellos Bioscience in a research note on Thursday, October 8th. They set a “buy” rating and a $24.00 target price for the company. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Satellos Bioscience in a research note on Monday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Wednesday, November 4th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.
Get Our Latest Stock Analysis on Satellos Bioscience
Satellos Bioscience Stock Performance
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Sell-side analysts predict that Satellos Bioscience will post -1.90 EPS for the current year.
Institutional Investors Weigh In On Satellos Bioscience
A hedge fund recently raised its stake in Satellos Bioscience stock. AWM Investment Company Inc. raised its holdings in shares of Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 41.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 305,000 shares of the company’s stock after buying an additional 90,000 shares during the quarter. AWM Investment Company Inc. owned about 1.46% of Satellos Bioscience worth $2,338,000 as of its most recent SEC filing.
Satellos Bioscience Company Profile
Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.
Featured Articles
- Five stocks we like better than Satellos Bioscience
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
